Better Therapeutics gains on additional data from diabetes treatment application

Better Therapeutics

11/10/2023 13:43

** Shares of Better Therapeutics  BTTX.O  rise ~72% to
64 cents before paring gains premarket 
    ** Co reports additional data from a pivotal study testing
its diabetes treatment application AspyreRx 
    ** BTTX says data who used a combination of AspyreRx and
standard of care, including GLP-1 drugs led to a "substantially
greater" improvement in their blood sugar levels vs those who
did not use AspyreRx 
    ** BTTX's AspyreRx, which is indicated to provide cognitive
behavioral therapy to patients 18 years or older with type 2
diabetes, recently received U.S. approval 
    ** GLP-1 drugs help control blood sugar in patients with
Type 2 diabetes and are also used as weight-loss treatments 
    ** As of last close, BTTX stock down ~66% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))